Neurooncology: 2025 update

Area of Science:

• Neuro-oncology
• Cancer Biology
• Epigenetics

Background:

• Brain tumor research is advancing, focusing on primary CNS tumors and brain metastasis.
• The tumor microenvironment, including cerebral microcirculation and hypoxia, significantly impacts metastatic progression.
• Glioblastoma exhibits intratumoral heterogeneity and distinct DNA methylation profiles, crucial for understanding tumor evolution.

Purpose of the Study:

• To highlight groundbreaking advancements in brain tumor research, focusing on the tumor microenvironment, epigenetics, and diagnostics.
• To explore the role of DNA methylation and histone serotonylation in glioblastoma and ependymoma.
• To present novel diagnostic and prognostic tools for improved patient care in neuro-oncology.

Main Methods:

• Analysis of DNA methylation profiles in recurrent glioblastoma.
• Investigation of the immune landscape and cell dynamics using single-cell phenotyping.
• Application of confocal laser microscopy and cerebrospinal fluid-derived cell-free DNA sequencing for diagnostics.

Main Results:

• Global DNA methylation identified as a diagnostic marker for IDH-wildtype glioblastoma.
• Histone serotonylation confirmed as a critical epigenetic regulator in ependymoma.
• Advanced histomorphological features and non-invasive liquid biopsies show promise for prognosis and diagnosis.

Conclusions:

• Understanding the tumor microenvironment, epigenetic modifications, and immune interactions is vital for brain tumor progression.
• Innovative diagnostic and prognostic tools are enhancing patient care and enabling personalized treatment strategies.
• These advancements represent significant progress in neuro-oncology, aiming for improved outcomes in brain tumor patients.